Spyre Therapeutics, Inc.
SYRE
$28.40
-$0.26-0.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 177.50M | 176.99M | 169.49M | 162.79M | 145.99M |
| Gross Profit | -177.50M | -176.99M | -169.49M | -162.79M | -145.99M |
| SG&A Expenses | 46.15M | 45.15M | 44.87M | 45.78M | 49.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 223.64M | 222.15M | 214.36M | 208.57M | 195.07M |
| Operating Income | -223.64M | -222.15M | -214.36M | -208.57M | -195.07M |
| Income Before Tax | -148.98M | -206.81M | -208.93M | -207.97M | -214.85M |
| Income Tax Expenses | -14.00K | 4.00K | 4.00K | 51.00K | 50.00K |
| Earnings from Continuing Operations | -148.97 | -206.81 | -208.93 | -208.02 | -214.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -148.97M | -206.81M | -208.93M | -208.02M | -214.90M |
| EBIT | -223.64M | -222.15M | -214.36M | -208.57M | -195.07M |
| EBITDA | -61.07M | -116.27M | -160.23M | -207.82M | -194.51M |
| EPS Basic | -1.20 | -2.11 | -2.18 | -2.31 | 9.23 |
| Normalized Basic EPS | -1.70 | -2.43 | -2.48 | -2.77 | -4.74 |
| EPS Diluted | -1.20 | -2.11 | -2.18 | -2.31 | 9.23 |
| Normalized Diluted EPS | -1.70 | -2.43 | -2.48 | -2.77 | -4.74 |
| Average Basic Shares Outstanding | 236.27M | 226.75M | 211.80M | 188.05M | 148.40M |
| Average Diluted Shares Outstanding | 236.27M | 226.75M | 211.80M | 188.05M | 148.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |